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Abstract Our understanding of the underlying molecular
mechanism of Parkinson’s disease (PD) ishampered by a lack
of access to affected human dopaminergic (DA) neurons on
which to base experimental research. Fortunately, the recent
development ofa PDdisease model using induced pluripotent
stem cells (iPSCs) provides access to cell types that were
previously unobtainable in sufficient quantity or quality, and
presents exciting promises for the elucidation of PD etiology
and the development of potential therapeutics. To more effec-
tively model PD, we generated two patient-derived iPSC
lines: a line carrying a homozygous p.G2019S mutation in
the leucine-rich repeat kinase 2 (LRRK2) gene and another
carrying a full gene triplication of the α-synuclein encoding
gene, SNCA. We demonstrated that these PD-linked pluripo-
tent lines were able to differentiate into DA neurons and that
these neurons exhibited increased expression of key oxidative
stress response genes and α-synuclein protein. Moreover,
when compared to wild-type DA neurons, LRRK2-G2019S
iPSC-derived DA neurons were more sensitive to caspase-3
activation caused by exposure to hydrogen peroxide, MG-
132, and 6-hydroxydopamine. In addition, SNCA-triplication
iPSC-derived DA neurons formed early ubiquitin-positive
puncta and were more sensitive to peak toxicity from hydro-
gen peroxide-induced stress. These aforementioned findings
suggest that LRRK2-G2019S and SNCA-triplication iPSC-
derived DA neurons exhibit early phenotypes linked to PD.
Given the high penetrance of the homozygous LRRK2 muta-
tion, the expression of wild-type α-synuclein protein in the
SNCA-triplication line, and the clinical resemblance of
patients afflicted with these familial disorders to sporadic PD
patients, these iPSC-derived neurons may be unique and
valuable models for disease diagnostics and development of
novel pharmacological agents for alleviation of relevant
disease phenotypes.
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Introduction
Neurodegenerative diseases are among the most intractable
of human disorders. Over 100 years after Alois Alzheimer
gave his first lecture on a patient with “a peculiar disorder of
the cerebral cortex,” and almost 200 years since James
Parkinson published his first description on the “shaking
palsy,” we continue to search for the mechanisms that un-
derlie the neurodegeneration in these eponymous diseases.
Pathologically, the neurodegenerative disorders include
Parkinson’s disease (PD), Alzheimer’s disease (AD), Hunting-
ton’s disease, amyotrophic lateral sclerosis, frontotemporal
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DOI 10.1007/s11910-012-0270-ydementia (FTD), and prion disease and are characterized by
protein aggregation, inclusion body formation, and eventual
significant neuronal loss. Our understanding of neurodegener-
ative disease pathogenesis has been spurred by the conver-
gence of two disciplines: the molecular characterization of
aggregating proteins in the diseased brain, and the identifica-
tion of familial forms of AD, PD, and FTD.
PD is a debilitating neurodegenerative disorder charac-
terized by a loss of neurons in the central nervous system
(CNS), particularly the dopaminergic neurons of the
substantia nigra pars compacta [1–6], but also in the locus
coeruleus, nucleus basalis of Meynert, and the dorsal
nucleus of the vagus nerve [7]. The majority of PD cases
result from unknown etiology, with the loss of dopaminergic
neurons of the substantia nigra pars compacta disrupting the
basal ganglia network of the midbrain, striatum, and cortex.
The disruption of the basal ganglia pathway leads to reduced
thalamus activity, which in turn fails to adequately control
cortical function through glutamatergic activation. The most
noticeable and severe consequence of this signal disruption
is a gradual decrease of motor cortex activity, especially in
the primary motor cortex and the supplementary motor area.
This gives rise to the cardinal PD clinical features of brady-
kinesia, rigidity, and tremor, while loss of dopaminergic
neurons in the olfactory bulb can lead to impairment of the
sense of smell [1–6, 8–11].
In PD, protein aggregates known as Lewy bodies and
Lewy neurites form in the neuronal soma and neuritic pro-
jections, respectively. Since the identification of these
lesions in the early 1920s and their subsequent characteriza-
tion by electron microscopy as structures comprised of
abnormal filaments in the 1960s, the presence of these
protein aggregates was considered integral to the observed
progressive CNS degeneration. However, the molecular
mechanisms underlying the initiation and progression of
PD remain largely elusive. Instrumental in our disease
model conception has been the identification of patients
with genetic variants that lead to autosomal-recessive
or -dominant forms of the disease. Mutations in GBA,
LRRK2, PARK2, PARK7 (DJ-1), PINK1, SNCA,o rUCHL1
can lead to monogenic forms of PD or increased PD
susceptibility, suggesting important roles for these proteins
in the pathogenesis of the disease [12–17]. Of the distinct
PD-related genetic alterations discovered, 500 relate to the
five most prominently represented genes: SNCA, LRRK2,
PARK2, PINK1,a n dPARK7, with genetic alterations in SNCA
and LRRK2 leading to autosomal-dominant forms of the
disease [12]. Notably, the genes identified in familial forms
of PD, FTD, and AD are linked to the proteins that aggregate
in both inherited and sporadic forms of those diseases.
The first such mutation identified was a p.Ala53Thr
mutation in the SNCA gene, which encodes α-synuclein,
while subsequent studies have found that other SNCA
mutants cause other inherited forms of PD. Intriguingly,
Lewy bodies were independently found to be principally
composed of the α-synuclein protein [18]. The existence
of autosomal-dominant SNCA mutations in combination
with the aggregation of the α-synuclein protein in the
diseased brain, suggests a key and perhaps causal role for
this protein—a conclusion that may extend to sporadic
forms of PD.
The remaining products of PD-related genes do not na-
tively aggregate, but they can be linked in direct and indirect
ways to protein degradation pathways: GBA encodes the key
lysosomal protein β-glucocerebrosidase; LRRK2 encodes an
enzyme called leucine-rich repeat kinase 2 that has a pre-
dicted kinase activity, but is associated with the organization
of lysosomes, endosomes, and other membranous organ-
elles; PARK2 is part of the E3 ubiquitin-ligase complex;
PARK7 protects cells against oxidative stress; PINK1 is
hypothesized to be protective against cell stress by phos-
phorylating mitochondrial proteins; UCHL1 is a neural-
specific ubiquitin-protein hydrolase. Taken together, the
genes affected by familial PD mutations yield an important
foundation on which to build our understanding of this
neurodegenerative disease.
α-Synuclein and LRRK2
α-Synuclein is a 17-kD protein with two human homologs,
β-synuclein and γ-synuclein. Robustly expressed through-
out the CNS and peripheral nervous system (PNS), α-
synuclein has long been considered to be a natively unstruc-
tured protein that is capable of taking on partially folded
amyloidogenic α-helical or β-sheet conformations [19].
However, more recent studies challenge this prevailing par-
adigm, by suggesting that endogenous α-synuclein in non-
denaturing conditions may form helically folded soluble
tetramers that resist aggregation [20￿￿].
Although the exact function of α-synuclein remains un-
known, the protein has been found in presynaptic vesicles,
thus leading to its original nomenclature from the Torpedo
ray. Further, α-synuclein has been shown to bind to lipids,
potentially via its imperfect 11 amino-acid repeats, and
associate with phospholipase D2 [21–23]. Taken together,
these results implicate α-synuclein in neurotransmitter
release, vesicle turnover, channel localization, and
dose-dependent dynamic dopamine release [24]. Recently,
Chandra et al. [25] and Burré et al. [26] demonstrated that
α-synuclein is required for presynaptic vesicle chaperoning
through SNARE-complex assembly by directly binding to
VAMP2. These findings further support a neural-specific
role for α-synuclein at the level of presynaptic vesicles.
α-Synuclein knockout animals appear to be relatively
unaffected—with conflicting literature reports suggesting
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tance, and neurotransmitter deficits [27, 28]. However, the
importance of α-synuclein should not be underestimated;
the presence and similarity of β-synuclein and γ-synuclein
in these knockout animals may compensate for the deficien-
cy of α-synuclein, masking critical processes that it is
involved in. Recent studies on complete synuclein-knockout
animals showed age-dependent neurological impairments
with premature death [29].
While SNCA whole-locus multiplications (duplication or
triplications) are perhaps the most relevant to sporadic
patients, as they encode a qualitatively wild-type protein
rather than a missense form, LRRK2 mutations are, by far,
the most common inherited form of PD. Studies in animal
and cellular models have shown that certain mutations in the
LRRK2 gene can increase its kinase activity, which contrib-
utes to neurotoxicity, possibly via the oxidative stress path-
way [30–33]. Moreover, cells expressing mutant LRRK2
have been shown to be more vulnerable to peroxide-
induced cell death than wild-type LRRK2 cells [6, 32].
Although the function of LRRK2 is currently not fully
understood, there is evidence that the reduced expression
of LRRK2 mRNA limits neural progenitor cell differentia-
tion toward dopaminergic neurons and may enhance cell
death [34]. These findings suggest that LRRK2 plays a
pivotal role in neuronal survival, and that the loss of
function in this gene might also be pathogenic for PD [35].
Models of Parkinson’s Disease
To understand the development and progression of a human
disease, an effective model that combines the genetic under-
pinnings with a similar, if not identical, phenotypic output is
required. The appreciable gaps in our understanding of the
mechanisms of PD initiation and progression, along with
other sporadic and genetic neurodegenerative diseases, can
be traced to the current lack of accurate models of these
complex human diseases. The standard process for model-
ing human disease with genetic origins has been to over-
express the human gene of interest in model organisms
(from yeast, to drosophila, to mouse, to non-human primate)
and then observe the cellular and protein response. Pertur-
bations that appear phenotypic are used as the fitness func-
tion for subsequent drug screening or therapeutic target
selection. These studies have provided some important
advances for a large spectrum of human disease, and have
been instrumental in our basic understanding of neurode-
generative diseases [33, 36–39].
However, the use of these transgenic models have failed
to develop an accurate portrait of the underlying disease
mechanisms. This unfortunate result should not be surprising.
While overexpression of human genes in model organisms
may constitute an accurate representation of the under-
lying human pathogenesis for some diseases, in complex
neurodegenerative diseases that involve endogenously
expressed human proteins, basic cellular machinery such
as transcriptional feedback, and stochastic balance of the
proteasomal pathway are bound to play significant roles.
These two fundamental cellular processes are greatly com-
promised in overexpression organism models: transcrip-
tional feedback is impossible when proteins are expressed
on a non-native promoter, or even a native promoter in a
different location in the genome, where epigenetics and
other sequence neighbor effects will undoubtedly play a
role in expression. The result is that mechanistic studies of
neurodegeneration have been thwarted by an inability to
study the cellular processes in susceptible human neurons
that had an endogenous predisposition to the disease.
The lack of studies employing human cells to investigate
human neurodegenerative disease is not due to a lack of
interest. PD is challenging to study due to the inaccessibility
of affected human midbrain dopaminergic (mDA) neurons
and a scarcity of animal models that mimic the key disease
features. The transgenic animals and cellular models
expressing known PD-associated genes have provided im-
portant insights into the pathogenesis of the disease; how-
ever, it has been difficult to demonstrate that the implicated
mechanisms are also present in neurons from affected
individuals.
Previous genetic studies have implicated several potential
mechanisms but the pathogenesis of PD remains largely
obscure. In most PD patients, Lewy bodies and Lewy neu-
rites form in both CNS and autonomic PNS neurons. These
large intracellular proteinaceous inclusions are rich in α-
synuclein and ubiquitin, an observation that suggests a role
for α-synuclein and the proteasome in the molecular devel-
opment of sporadic and inherited PD [40]. However, not all
patients with PD develop Lewy bodies. Although mutations
in LRRK2 are commonly associated with PD and Lewy
body pathology, some of these patients do not exhibit a
Lewy phenotype. Therefore, it is thought that protein aggre-
gration may actually be a disease modifier rather than direct
cause [41]. Methods to identify patients with a well-defined
aggregation phenotype may be useful in categorizing dis-
ease, as well as in correctly targeting disease-modifying
interventions to an appropriate class of patients.
As discussed, autosomal-dominant forms of PD have
been documented in families with SNCA missense muta-
tions or gene duplication/triplications. α-Synuclein protein
aggregation and markers of cellular stress are also seen in
other neurodegenerative disorders, including multiple sys-
tem atrophy, Bradbury-Eggleston syndrome, and dementia
with Lewy bodies.
The selective degeneration of neural subtypes in each
disease has since been linked to the resulting cornucopia
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dence suggests that the true culprit of cellular toxicity may
be the soluble cytoplasmic oligomeric α-synuclein protein,
whereas the large insoluble protein aggregates may in fact
represent a cellular defense mechanism in which the cell
sequesters cytotoxic-soluble oligomeric proteins into insol-
uble inclusion bodies [42].
Attempting to replicate the cardinal phenotypic features
of PD, researchers have made use of animal models of
dopaminergic neurotoxicity, and transgenic models of the
familial PD-causing genes. In drosophila, overexpression of
SNCA leads to age-dependent dopaminergic neuron degen-
eration. Also, transgenic mice overexpressing mouse and
human SNCA exhibit pathological phenotypes—inclusion
body formation in some CNS cells, slight impairment in
motor control, and loss of dopaminergic neuron terminals in
the basal ganglia. These results from transgenic models
support a causal role for α-synuclein in the development
of PD [43–45]. Furthermore, the experiments using
LRRK2-G2019S transgenic mouse models demonstrated
age-dependent and levodopa-responsive slowness of
movement associated with diminished dopamine release
and axonal pathology [46].
Taking together this body of evidence and the known
inherited forms of PD, one can construct a basic PD model:
α-synuclein begins to aggregate, through some innate mech-
anism, or induced by other factors; the cell recognizes the
buildup of cytosolic α-synuclein levels and attempts to
degrade the proteins by ubiquitination, and subsequent shut-
tling to a proteasome for degradation. In the diseased brain,
any one of the following processes could be disturbed: the
innate dynamic aggregation of α-synuclein, the regulation
of α-synuclein expression level, ubiquitination of α-
synuclein, and degradation of α-synuclein degradation. In-
terestingly, Lewy bodies generally contain high concentra-
tions of ubiquitin, suggesting unfruitful attempts by the
cellular proteasomal pathway to degrade α-synuclein de-
spite substantial poly-ubiquitination.
In sum, while it has been shown that overexpression of α-
synuclein transgenes leads to protein aggregation in normal
cells, the study of native processes leading to aggregation in
affected individuals has been hindered by the inaccessibility
of human neurons in vivo, the limitations inherent in studying
postmortem samples from PD patients, and the inability to
accurately recapitulate human disease in transgenic models
[47–49].
Induced Pluripotent Stem Cells
The development of human induced pluripotent stem cells
(iPSCs) in 2007 by Takahashi et al. [50] and Yu et al. [51]
has presented a novel approach to study human diseases.
Where researchers were previously restricted to studying
human proteins in virally induced overexpression animal
models, or, at best, a zinc-finger cleaved recombination on
a native promoter, we are now able to generate stable plu-
ripotent lines from patients with inherited forms of disease,
with their endogenous genome and its transcriptional feed-
backs largely intact.
To explore the potential use of iPSC-derived neurons in
detecting protein accumulation and aggregation phenotypes,
we selected two PD-causing genotypes: the homozygous
G2019S point mutation in the LRRK2 gene, which causes
autosomal-dominant PD, and the heterozygous triplication
of the SNCA locus (total: four functional gene copies),
which also causes autosomal-dominant PD. In keeping with
a dominant mode of inheritance, in the vast majority of
LRRK2-PD patients a single heterozygous G2019S muta-
tion is present; however, rare patients with homozygous
G2019S mutation have also been reported (mostly due to
parental consanguinity), resulting in a similar phenotype.
LRRK2-G2019S had previously been identified in 0.6–
1.6% and 2–8% of sporadic and familial PD, respectively
[52–54]. The penetrance of this particular mutation is age-
dependent, increasing from 17% penetrance at age 50–85%
at age 70 years [55]. Clinical symptoms associated with PD
in individuals carrying the LRRK2-G2019S mutation are
mostly indistinguishable from those affected by late-onset
idiopathic PD with pathologies affecting both motor and
non-motor bodily functions [56].
α-Synuclein expression level is known to influence dis-
ease progression with triplications causing earlier onset and
more rapid progression than duplications [17, 49, 57, 58].
Due to this pronounced phenotype in patients, SNCA
triplication genotype was selected to provide the highest
probability of detecting disease-related phenotypes that
may be useful in categorizing disease characteristics in
patient-specific iPSC-derived neurons.
Although derivation of iPSC lines from idiopathic PD
patients has been reported, it is still not known whether
these PD iPSCs can give rise to mDA neurons that
exhibit native phenotypes related to PD in vitro [59,
60]. As PD is likely to result from a combination of
genetic and environmental factors, it is not clear to what
extent sporadic PD lines will demonstrate phenotypes
that are clearly discernible; thus, proof-of-principle dem-
onstrations that iPSC lines recapitulate key phenotypes of
PD may be most effectively achieved using cells from
patients with monogenic mutations. Recent work by Is-
rael et al. [61￿￿] has demonstrated the utility of iPSC
modeling for AD, suggestingi P S Cm o d e l i n gm a yb e
broadly applicable to neurodegenerative diseases. Gener-
ation of PD phenotypes from iPSC-derived neurons
would be useful for studies aimed at understanding dis-
ease mechanism, prevention, and treatment.
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iPSCs offer a new platform for studying human diseases in
the most endogenous form possible when patient primary
cell lines are unavailable [62￿, 63￿]. Further, differentiation
and maturation of the IPSCs enable the study of disease
phenotypes during development and aging of the cell type of
interest. Using this approach, we have demonstrated a caus-
al role of SNCA-triplication and LRRK2-G2019S in devel-
oping PD-related phenotypes. Broadly speaking, iPSC
models may be readily extended to other neurodegenerative
diseases with genomic mutations underpinnings, and is not
just limited to PD [61￿￿, 64, 65].
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